menu
    • menu
    [{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAXONA Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAXONA Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by MAXONA Pharmaceuticals

    Menu

    MAXONA Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maxona Pharmaceuticals Announces MAX-OO1 Phase 1 Clinical Program Results

                            Details : MAX-001 (Nefopam HCl) is a non-opioid, non-NSAID oral therapy, which is currently being evaluated for the treatment of patients with acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maxona Pharmaceuticals Exits Stealth, Advances MAX-001 First-To-Market Candidate

                            Details : The company's initial focus is on advancing MAX-001 as a safe and highly effective non-opioid option for the treatment of acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth